MedTrace Logo

The Effects of Xuezhikang and Atorvastatin on Lipid in Patients With Dyslipidemia and Prediabetes

NCT06750783 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 398

Last updated 2025-04-03

No results posted yet for this study

Summary

This study compares the impact of Xuezhikang and atorvastatin on glucose metabolism to explore the incidence of prediabetes patients developing diabetes after 24 weeks of Xuezhikang use, and by investigating the effect of Xuezhikang on blood glucose fluctuations, discusses the possible mechanisms by which Xuezhikang affects glucose metabolism.

Conditions

  • Prediabetic State (IGT)

Interventions

DRUG

Xuezhikang

The Xuezhikang group takes Xuezhikang at a dose of 600 milligrams twice a day, orally after meals;

DRUG

Atorvastatin

The atorvastatin group takes atorvastatin 20mg once a day, orally after meals.

Sponsors & Collaborators

  • Beijing Tsinghua Chang Gung Hospital

    lead OTHER

Principal Investigators

  • lixia jin, phD · Beijing Tsinghua Changgeng Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-31
Primary Completion
2026-03-31
Completion
2026-03-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06750783 on ClinicalTrials.gov